August 25, 2023.

Atmo Biosciences is one of only five businesses accepted into the market-leading ANDHealth+ commercialization program, which helps digital health companies to scale their products nationally and internationally.

August 10, 2023.

Atmo Biosciences today announced it has commenced a pivotal clinical study to assess the use of the Atmo Gas Capsule to measure gastrointestinal transit time in patients with suspected motility disorders.

The study involves simultaneous ingestion of the Atmo Gas Capsule and predicate device SmartPill to demonstrate the ability of Atmo’s gas-sensing capsule to assess whole and regional gut transit. Clinicians evaluate regional gut transit to help diagnose motility disorders such as gastroparesis (delayed emptying from the stomach), and slow transit constipation (slow transit through the colon).

15 May, 2023.

A Western Sydney University (WSU) and Monash University comparative study has validated the Atmo Gas Capsule relative to the SmartPill when measuring gastric emptying time and colonic transit time in patients with gastroparesis and chronic constipation.

Dr Jerry Zhou, lecturer and clinical researcher at WSU School of Medicine, presented findings from the study in a poster presentation at Digestive Disease Week  (DDW), held May 6-9 in Chicago.

17 April, 2023.

Atmo Biosciences is strengthening its U.S. focus with the appointment of experienced medical device executive Chris Bertrand to the Atmo Board and establishment of a San Diego, California office.

Atmo Biosciences has raised A$8 million in a fully subscribed Series B funding round.

The raise was led by Japanese multinational company Otsuka Pharmaceutical, an existing strategic shareholder that took up more than its pro rata entitlement.

Atmo Biosciences is pleased to announce that it has successfully completed the audit of its Quality Management System to obtain ISO 13485:2016 accreditation.

Atmo Biosciences is pleased to announce that the European Patent Office and IP Australia have each granted patents related to key intellectual property for Atmo’s ingestible gas sensor capsule, providing coverage until 2037.  

Atmo Biosciences is pleased to announce publication of a clinical study demonstrating strong agreement between data from Atmo’s world-first ingestible gas-sensing capsule and and a validated, FDA-cleared Wireless Motility Capsule (WMC), in determining transit metrics in healthy subjects.

Atmo Biosciences is pleased to announce that the US Patent and Trademark Office (USPTO) has granted the patent for Atmo’s ingestible gas sensor capsule.